
AN2 Therapeutics Moves Oral Epetraborole into Phase 2 for Polycythemia Vera
AN2 Therapeutics, Inc. Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics derived from its proprietary boron chemistry platform, today announced plans…












